

VALIDIAN CORP
Form 10QSB
November 19, 2007

OMB APPROVAL

OMB Number:
3235-0416

Expires: April 30,
2009

Estimated average
burden

hours per response
182.00

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-QSB

[x]

**QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF
1934**

FOR THE QUARTERLY PERIOD ENDED September 30, 2007

[]

TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT

Commission File No. 000-28423

VALIDIAN CORPORATION

(Exact name of small business issuer as specified in its charter)

NEVADA

58-2541997

(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)

30 Metcalfe Street, Ottawa, Ontario, Canada K1P 5L4

(Address of principal executive offices)

Issuer s telephone number: 613-230-7211

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No []

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [] No [X]

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 48,377,597 Shares of the issuer's Common Stock were outstanding as of November 9, 2007.

Transitional Small Business Disclosure Format: Yes [] No [X]

SEC 2334 (11-06)

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1

PART I FINANCIAL INFORMATION**Item 1. Financial Statements**

VALIDIAN CORPORATION AND SUBSIDIARIES
A DEVELOPMENT STAGE ENTERPRISE
CONSOLIDATED CONDENSED BALANCE SHEETS

	September 30, 2007 (Unaudited)	December 31, 2006
Assets		
Current assets:		
Cash and cash equivalents	\$ 1,544	\$ 7,780
Accounts receivable	18,756	14,628
Prepaid expenses	81,430	154,674
	101,730	177,082
Property and equipment, net of accumulated depreciation of \$223,719		
(December 31, 2006 - \$196,598)	8,735	34,971
Deferred financing costs, net of accumulated amortization of \$110,527		
(December 31, 2006 - \$50,528) (note 2)	102,343	169,403
Total assets	\$ 212,808	\$ 381,456
Liabilities and Stockholders Deficiency		
Current liabilities:		
Accounts payable and accrued liabilities (note 9)	\$ 1,826,398	\$ 1,215,514
Promissory notes payable (note 3)	199,833	603,928
Deferred revenue	155,000	155,000
Current portion of capital lease obligation	3,347	5,084
Current portion of 10% Senior convertible notes (note 4)	1,176,728	--

Edgar Filing: VALIDIAN CORP - Form 10QSB

Total current liabilities	3,361,306	1,979,526
10% Senior convertible notes (note 4)	1,207,317	706,803
Capital lease obligation	--	1,466
Total liabilities	4,568,623	2,687,795
Stockholders' Deficiency (note 5):		
Common stock, (\$0.001 par value. Authorized 100,000,000 shares;		
issued and outstanding 47,567,597 and 39,212,069 shares at	47,567	39,212
September 30, 2007 and December 31, 2006, respectively.)		
Preferred stock (\$0.001 par value. Authorized 7,000,000 shares; issued and outstanding Nil shares at September 30, 2007 and at December 31,	--	--
2006)		
Additional paid in capital	23,177,940	22,326,065
Deficit accumulated during the development stage	(27,552,888)	(24,643,182)
Retained earnings prior to entering development stage	21,304	21,304
Treasury stock (7,000 shares at June 30, 2007 and December 31, 2006,	(49,738)	(49,738)
at cost)		
Total stockholders' deficiency	(4,355,815)	(2,306,339)
Basis of presentation (note 1)		
Commitments (note 10)		
Subsequent events (note 12)		
Total liabilities and stockholders' deficiency	\$212,808	\$381,456

See accompanying notes to unaudited interim consolidated condensed financial statements.

VALIDIAN CORPORATION AND SUBSIDIARIES**A DEVELOPMENT STAGE ENTERPRISE****Consolidated Condensed Statements of Operations****For the three and nine months ended September 30, 2007 and 2006****And for the Period from August 3, 1999 to September 30, 2007****(Unaudited)**

	Three Months		Nine Months		Period from
	Ended		Ended		August 3, 1999
	September 30,		September 30,		to
	2007	2006	2007	2006	September 30,
					2007
Operating expenses (income):					
Selling, general and administrative (note 10)	\$418,121	\$ 481,349	\$ 1,348,354	\$ 1,476,149	\$12,722,692
Research and development	35,276	192,496	626,262	792,487	8,726,974
Depreciation of property and equipment	4,712	14,745	27,121	47,707	413,708
Gain on sale of property and equipment	--	--	--	--	(7,442)
Write-off of prepaid services	--	--	--	--	496,869
Write-off of deferred consulting services	--	--	--	--	1,048,100
Write-off of accounts receivable	--	--	--	--	16,715
Write-off of due from related party	--	--	--	--	12,575
Loss on cash pledged as collateral for operating lease	--	--	--	--	21,926
Write-down of property and equipment	--	--	--	--	14,750
	458,109	688,590	2,001,737	2,316,343	23,466,867
Loss before other income (expenses)	(458,109)	(688,590)	(2,001,737)	(2,316,343)	(23,446,867)
Other income (expenses):					
Interest income	19	32	213	195	61,448
	--	34,347	(102,893)	34,347	69,917

Edgar Filing: VALIDIAN CORP - Form 10QSB

Gain (loss) on extinguishment of debt (note 7)					
Interest and financing costs (note 6)	(295,068)	(127,761)	(721,645)	(191,604)	(4,076,365)
Other	(37,983)	(3,994)	(83,644)	(4,223)	(141,021)
	(333,032)	(97,376)	(907,969)	(161,285)	(4,086,021)
Net loss	\$(791,141)	\$(785,966)	\$(2,909,706)	\$(2,477,628)	\$(27,552,888)
Loss per share basic and diluted (note 8)	\$(0.02)	\$(0.02)	\$(0.06)	\$(0.07)	
Weighted average number of common shares outstanding during period	47,517,841	35,617,843	46,110,740	34,039,303	

See accompanying notes to unaudited interim consolidated condensed financial statements.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Consolidated Statements of Changes in Stockholders Equity (Deficiency) and Comprehensive Loss

For the period from December 31, 1998 to September 30, 2007

(Unaudited)

	Number	Common stock amount	Additional paid-in capital	Retained earnings prior to entering development stage	Deficit accumulated during development stage	Accumulated other compre- hensive income (loss)	Treasury stock	Total
Balances at December 31, 1998	61,333	\$ 61	\$ 23,058	\$ 30,080	\$	\$ (7,426)	\$	\$ 45,773
Issued for mining claims	92,591	92	27,408					27,500
Issued for cash	3,000,000	3,000	27,000					30,000
Reverse acquisition	8,459,000	8,459	21,541					30,000
Fair value of warrants issued to unrelated parties			130,000					130,000
Shares issued upon exercise of warrants	380,000	380	759,620					760,000
Share issuance costs			(34,750)					(34,750)
Comprehensive loss:								
Net loss				(8,776)	(743,410)			(752,186)
Currency translation						11,837		11,837

Edgar Filing: VALIDIAN CORP - Form 10QSB

adjustment								
Comprehensive loss								(740,349)
Balances at December 31, 1999	11,992,924	11,992	953,877	21,304	(743,410)	4,411		248,174
Shares issued upon exercise of warrants	620,000	620	1,239,380					1,240,000
Share issuance costs			(62,000)					(62,000)
Acquisition of common stock						(49,738)		(49,738)
Comprehensive loss:								
Net loss					(2,932,430)			(2,932,430)
Currency translation adjustment						(40,401)		(40,401)
Comprehensive loss								(2,972,831)
Balances at December 31, 2000	12,612,924	12,612	2,131,257	21,304	(3,675,840)	(35,990)	(49,738)	(1,596,395)
Shares issued in exchange for debt	2,774,362	2,774	2,216,715					2,219,489
Fair value of warrants issued to unrelated parties			451,500					451,500
Comprehensive loss:								
Net loss					(1,448,485)			(1,448,485)
Currency translation adjustment						62,202		62,202
Comprehensive loss								(1,386,283)
Balances at December 31, 2001	15,387,286	\$15,386	\$4,799,472	\$21,304	\$(5,124,325)	\$26,212	\$(49,738)	\$(311,689)

See accompanying notes to unaudited interim consolidated condensed financial statements.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) and Comprehensive Loss

For the period from December 31, 1998 to September 30, 2007

(Unaudited)

	Common stock Number	Additional paid-in capital amount	development stage stage	Retained earnings prior to entering accumulated during development stage	Deficit Accumulated during development stage	Accumulated other compre- hensive income (loss)	Treasury stock	Total
Balances at December 31, 2001	15,387,286	\$ 15,386	\$ 4,799,472	\$ 21,304	\$(5,124,325)	\$ 26,212	\$ (49,738)	\$ (311,689)
Shares issued in consideration of consulting services	340,500	340	245,810					246,150
Comprehensive loss:								
Net loss					(906,841)			(906,841)
Currency translation adjustment on liquidation of investment in foreign subsidiary						(26,212)		(26,212)

Edgar Filing: VALIDIAN CORP - Form 10QSB

Comprehensive loss							(933,053)
Balances at December 31,							
2002	15,727,786	15,726	5,045,282	21,304	(6,031,166)	(49,738)	(998,592)
Shares issued in exchange for debt	4,416,862	4,417	1,453,147				1,457,564
Shares issued in consideration of consulting and financing services	422,900	423	230,448				230,871
Fair value of warrants issued to unrelated parties for services			2,896,042				2,896,042
Fair value of stock purchase options issued to unrelated parties for services			597,102				597,102
Relative fair value of warrants issued to investors in conjunction with 4% senior subordinated convertible debentures			355,186				355,186
Intrinsic value of beneficial conversion feature on 4% convertible debentures issued to unrelated parties			244,814				244,814
Net loss and comprehensive loss					(3,001,900)		(3,001,900)

Edgar Filing: VALIDIAN CORP - Form 10QSB

Balances at	20,567,548	\$ 10,822,021	\$ 21,304	\$(9,033,066)	\$	\$(49,738)	\$1,781,087
December 31,		20,566					
2003							

See accompanying notes to unaudited interim consolidated condensed financial statements.

5

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Consolidated Statements of Changes in Stockholders Equity (Deficiency) and Comprehensive Loss

For the period from December 31, 1998 to September 30, 2007

(Unaudited)

	Number	Common stock amount	Additional paid-in capital	Retained earnings prior to entering development stage	Deficit accumulated during development stage	Accumulated other comprehensive income (loss)	Treasury stock	Total
Balances at December 31, 2003	20,567,548	\$20,566	\$10,822,021	\$21,304	\$(9,033,066)	\$	\$(49,738)	\$1,781,087
Shares issued in exchange for debt	464,000	464	429,536					430,000
Shares issued on conversion of 4% senior subordinated convertible debentures	2,482,939	2,483	1,238,986					1,241,469
Deferred financing costs transferred to additional paid in capital on conversion of 4% senior subordinated convertible debentures into common shares							(721,097)	(721,097)

Edgar Filing: VALIDIAN CORP - Form 10QSB

Shares issued pursuant to private placement of common shares and warrants	6,666,666	6,667	5,993,333					6,000,000
Cost of share issuance pursuant to private placement			(534,874)					(534,874)
Shares issued in consideration of consulting and financing services	70,000	70	72,730					72,800
Shares issued in consideration of penalties on late registration of shares underlying the 4% senior subordinated convertible debentures	184,000	184	110,216					110,400
Fair value of stock purchase warrants issued to unrelated parties for services			809,750					809,750
Relative fair value of warrants issued to investors in conjunction with 4% senior subordinated convertible debentures		\$	\$ 861,522	\$	\$	\$	\$	\$ 861,522

See accompanying notes to unaudited interim consolidated condensed financial statements.

6

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) and Comprehensive Loss

For the period from December 31, 1998 to September 30, 2007

(Unaudited)

	Number	Common stock amount	Additional paid-in capital	Retained earnings prior to entering development stage	Deficit accumulated during development stage	Accumulated other comprehensive income (loss)	Treasury stock	Total
Intrinsic value of beneficial conversion feature on 4% convertible debentures issued to unrelated parties			538,478					538,478
Net loss and comprehensive loss					(8,017,166)			(8,017,166)
Balances at December 31, 2004	30,435,153	30,434	19,620,601	21,304	(17,050,232)		(49,738)	2,572,369
Shares issued on conversion of 4% senior subordinated convertible debentures	1,157,866	1,158	577,774					578,932
Shares issued in settlement of 4% senior subordinated								

Edgar Filing: VALIDIAN CORP - Form 10QSB

convertible debentures at maturity	485,672	486	242,349					242,835
Deferred financing costs transferred to additional paid in capital on conversion of 4% senior subordinated convertible debentures into common shares			(163,980)					(163,980)
Fair value of stock purchase options issued to unrelated parties for services rendered			211,496					211,496
Fair value of modifications to stock purchase warrants previously issued to unrelated parties			61,162					61,162
Shares issued on the exercise of stock purchase warrants	805,000	805	401,695					402,500
Net loss and comprehensive loss						(4,205,659)		(4,205,659)
Balances at December 31, 2005	32,883,691	\$ 32,883	\$20,951,097	\$ 21,304	\$	\$	- \$(49,738)	\$ (300,345)
					(21,255,891)			

See accompanying notes to unaudited interim consolidated condensed financial statements.

7

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) and Comprehensive Loss

For the period from December 31, 1998 to September 30, 2007

(Unaudited)

	Number	Common stock amount	Additional paid-in capital	Retained earnings prior to entering development stage	Deficit accumulated during development stage	Accumulated other comprehensive income (loss)	Treasury stock	Total
Balances at December 31, 2005	32,883,691	\$ 32,883	\$20,951,097	\$ 21,304	\$ (21,255,891)	\$	\$ (49,738)	\$ (300,345)
Shares issued in consideration of consulting services	800,000	800	106,700					107,500
Fair value of employee stock options earned during period			28,689					28,689
Reversal of fair value of unvested employee stock options recognized in the current and prior periods, on forfeiture of the options			(9,939)					(9,939)
Shares issued on the exercise of stock purchase warrants	20,000	20	9,980					10,000

Edgar Filing: VALIDIAN CORP - Form 10QSB

Shares issued pursuant to the terms of the 10% senior convertible notes	2,800,000	2,800	401,602	404,402
Shares issued pursuant to the terms of the 10% promissory note	1,000,000	1,000	149,000	150,000
Shares issued pursuant to the terms of an agreement to extend the payment terms of finance fees payable	100,000	100	11,400	11,500
Shares issued in satisfaction of finance fees payable, which were included in accounts payable and accrued liabilities	250,000	250	28,500	28,750
Intrinsic value of beneficial conversion feature on the 10% senior convertible notes			515,297	515,297
Shares issued in satisfaction of interest payable	118,378	119	13,518	13,637
Shares issued in satisfaction of				

penalty for non-timely payment of the 10% promissory note	500,000	500	44,500					45,000
Shares issued in consideration for finance fees related to the issuance of convertible and promissory notes	740,000	740	75,720					76,460
Net loss and comprehensive loss					(3,387,291)			(3,387,291)
Balances at December 31, 2006	39,212,069	\$ 39,212	\$22,326,065	\$ 21,304		\$	\$	- \$(49,738) \$(2,306,339)
					(24,643,182)			

See accompanying notes to unaudited interim consolidated condensed financial statements

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) and Comprehensive Loss

For the period from December 31, 1998 to September 30, 2007

(Unaudited)

	Number	Common stock amount	Additional paid-in capital	Retained earnings prior to entering development stage	Deficit accumulated during development stage	Accumulated other comprehensive income (loss)	Treasury stock	Total
Balances at December 31, 2006	39,212,069	\$ 39,212	\$22,326,065	\$ 21,304	\$ (24,643,182)	\$ -	\$(49,738)	(2,306,339)
Shares issued in consideration of consulting services rendered and to be rendered	4,025,000	4,025	172,125					176,150
Shares issued in consideration of finance fees relating to the issuance of 10% senior convertible notes (note 5(a))	149,333	149	6,510					6,659
Shares issued in settlement of								

Edgar Filing: VALIDIAN CORP - Form 10QSB

accrued liabilities (note 5(a))	1,275,000	1,275	45,900	47,175
Shares issued in settlement of accrued interest on the 10% senior convertible notes	659,001	659	39,228	39,887
Fair value of employee stock options earned during the period			2,727	2,727
Incremental value of stock options issued during the period in exchange for the repurchase and cancellation of options previously issued (note 5(c))			106,933	106,933
Shares issued pursuant to the terms of the 10% senior convertible notes (note 4)	1,675,000	1,675	105,991	107,666
Intrinsic value of the beneficial conversion feature of the 10% senior convertible notes (note 4)			87,846	87,846

Shares issued on conversion of 10% senior convertible notes (note 4)	572,194	572	52,455				53,027
Relative fair value of warrants issued pursuant to the terms of the 10% senior convertible notes (note 4)			102,515				102,515
Fair value of warrants issued in consideration of consulting services rendered (note 5(b))			108,675				108,675
Fair value of options issued in consideration of consulting services rendered and to be rendered (note 5(c))			20,970				20,970
Net loss and comprehensive loss					(2,909,706)		(2,909,706)
Balances at September 30, 2007	47,567,597	\$47,567	\$23,177,940	\$21,304	\$(27,552,888)	\$(49,738)	\$(4,355,815)

See accompanying notes to unaudited interim consolidated condensed financial statements

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

For the nine months ended September 30, 2007 and 2006

And for the Period from August 3, 1999 to September 30, 2007

(Unaudited)

	Nine Months Ended September 30,		Period from August 3, 1999 to September 30, 2007
	2007	2006	
Cash flows from operating activities:			
Net loss		\$ \$(2,477,628)	\$ (27,552,888)
	(2,909,706)		
<i>Adjustments to reconcile net loss to net cash used in</i>			
<i>Operating activities:</i>			
Depreciation of property and equipment	27,121	47,707	413,708
Stock-based compensation	460,696	210,366	3,000,270
Non-cash interest and financing expense	720,703	189,474	4,071,420
Loss (gain) on extinguishment of debt and accrued liabilities (note 7)	102,893	(34,347)	(69,917)
Non-cash penalties	--	11,500	166,900
Write-off of prepaid services	--	--	496,869
Write-off of deferred consulting services	--	--	1,048,100
Currency translation adjustment on liquidation of			
investment in foreign subsidiary	--	--	(26,212)
Gain on sale of property and equipment	--	--	(7,442)
Write-off of accounts receivable	--	--	16,715
Write-off of due to related party	--	--	12,575
Loss on cash pledged as collateral for operating lease	--	--	21,926
Write-down of property and equipment	--	--	14,750

Increase (decrease) in cash resulting from changes in:

Accounts receivable	(4,128)	63,195	7,046
Prepaid expenses	(855)	(13,256)	(137,987)
Accounts payable and accrued liabilities	749,425	686,222	3,313,537
Deferred revenue	--	130,000	155,000
Due to a related party	--	--	(5,178)
Net cash used in operating activities	(853,851)	(1,186,767)	(15,060,808)

Cash flows from investing activities:

Additions to property and equipment	(884)	--	(527,427)
Proceeds on sale of property and equipment	--	--	176,890
Cash pledged as collateral for operating lease	--	--	(21,926)
Net cash used in investing activities	(884)	--	(372,463)

Cash flows from financing activities:

Capital lease repayments	(3,203)	(2,576)	(11,419)
Issuance of promissory notes payable	232,312	551,177	3,927,505
Issuance of 10% senior convertible notes	625,000	600,000	2,025,000
Debt issuance costs	(5,610)	(36,500)	(919,983)
Proceeds from exercise of stock purchase warrants	--	10,000	412,500
Increase in due from related party	--	--	12,575
Issuance of common shares	--	--	8,030,000
Redemption of common stock	--	--	(49,738)
Issuance of 4% senior subordinated convertible debentures	--	--	2,000,000
Repayment of promissory notes	--	(4,610)	(44,855)
Net cash provided by financing activities	848,499	1,117,491	15,381,585

Effects of exchange rates on cash and cash equivalents	--	--	18,431
--	----	----	--------

Net increase (decrease) in cash and cash equivalents	(6,236)	(69,276)	(33,255)
--	---------	----------	----------

Cash and cash equivalents:

Beginning of period	7,780	71,193	34,799
End of period	\$ 1,544	\$ 1,917	\$ 1,544

See accompanying notes to unaudited interim period consolidated condensed financial statements.

10

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

Validian Corporation (the Company) was incorporated in the State of Nevada on April 12, 1989 as CCC Funding Corp. The Company underwent several name changes before being renamed to Validian Corporation on January 28, 2003.

Since August 3, 1999, the efforts of the Company have been devoted primarily to the development of a high speed, highly secure method of exchanging data files using the internet, and to the sale and marketing of the Company's products. Prior to August 3, 1999, the Company conducted business in an unrelated field. As the Company commenced development activities on this date, it is considered for financial accounting purposes to be a development stage enterprise and August 3, 1999 is the commencement of the development stage.

1. Basis of Presentation

The accompanying consolidated condensed financial statements include the accounts of Validian Corporation and its wholly owned subsidiaries (collectively, the "Company") after elimination of all significant intercompany balances and transactions. The financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. While management has based its assumptions and estimates on the facts and circumstances currently known, final amounts may differ from such estimates.

The interim financial statements contained herein are unaudited but, in the opinion of management, include all adjustments (consisting only of normal recurring entries) necessary for a fair presentation of the financial position and results of operations of the Company for the periods presented. The results of operations for the nine months ended September 30, 2007 are not necessarily indicative of the operating results for the full fiscal year ending December 31, 2007. Moreover, these financial statements do not purport to contain complete disclosure in conformity with generally accepted accounting principles used in the United States of America and should be read in conjunction with the Company's audited financial statements as at and for the year ended December 31, 2006.

The consolidated condensed financial statements have been prepared assuming that the Company will continue as a going concern. The Company has no revenues, has a stockholders' deficiency of \$4,355,815 as at September 30, 2007, and has incurred a loss of \$2,909,706 and negative cash flow from operations of \$853,851 for the nine months then ended. The Company also expects to continue to incur operating losses for the foreseeable future, and has no lines of credit or other financing facilities in place.

The Company expects to incur operating expenditures of approximately \$2.6 million for the year ending December 31, 2007. In the event the Company cannot raise the additional funds necessary to finance its research and development and sales and marketing activities, it may have to cease operations.

All of the factors above raise substantial doubt about the Company's ability to continue as a going concern. Management's plan to address these issues includes raising capital through the private placement of equity, the exercise of previously-issued equity instruments and through the issuance of additional promissory notes. The Company's ability to continue as a going concern is subject to management's ability to successfully implement these plans. Failure to do so could have a material adverse effect on the Company's position and or results of operations and could also result in the Company ceasing operations. The consolidated financial statements do not include adjustments that would be required if the assets are not realized and the liabilities settled in the normal course of operations.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

1. Basis of Presentation (continued)

Even if successful in obtaining financing in the near term, the Company cannot be certain that cash generated from its future operations will be sufficient to satisfy its liquidity requirements in the longer term, and it may need to continue to raise capital by issuing additional equity or by obtaining credit facilities. The Company's future capital requirements will depend on many factors, including, but not limited to, the market acceptance of its products and the level of its promotional activities and advertising required to generate product sales. No assurance can be given that any such additional funding will be available or that, if available, it can be obtained on terms favorable to the Company.

2. Deferred financing costs

During the nine months ended September 30, 2007 the Company issued \$625,000 in principal amount of its 10% senior convertible notes (note 4). In connection with the placement of these notes, the Company incurred costs totaling \$29,570, of which \$20,610 was paid or payable in cash and \$8,960 was paid through the issuance of 149,333 common shares of the Company. These costs are being amortized on an effective interest-rate basis over the term of the respective notes.

Amortization of the deferred financing costs is included in interest and financing costs.

3. Promissory notes payable

The promissory notes payable bear interest at 12%, are due on demand, and are unsecured.

During the nine months ended September 30, 2007, the Company issued \$226,832 in principal amount of its promissory notes. Also during the nine months ended September 30, 2007 the Company issued \$810,000 principal amount of its 10% senior convertible notes in consideration for the cancellation of \$636,407 in principal of and \$173,593 in accrued interest on its promissory notes (note 4).

12

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

4. 10% Senior convertible notes

The following table sets forth the financial statement presentation of the note proceeds on issuance, and the changes in financial statement presentation of the balance allocated to the notes at September 30, 2007 and December 31, 2006:

	Nine months Ended September 30, 2007	Year Ended December 31, 2006
Balance beginning of period	\$ 706,803	\$ --
Note proceeds on issuance	1,435,000	1,400,000
Allocated to common stock and additional paid-in capital for market value of stock issued to holders of the notes:		
Allocated to common stock	(1,675)	(2,800)
Allocated to additional paid-in capital	(105,991)	(401,402)
	(107,666)	(404,402)
Allocated to additional paid-in capital for the relative fair value of warrants issued to holders of the notes	(102,515)	--
Allocated to additional paid-in capital for the intrinsic value of the beneficial conversion feature	(87,846)	(515,297)
Proceeds allocated to 10% senior convertible notes on issuance	1,136,973	480,301

Edgar Filing: VALIDIAN CORP - Form 10QSB

Accretion recorded as a charge to interest and financing costs	413,035	164,599
Principal converted pursuant to the terms of the note (note 5(a))	(50,000)	--
Loss on extinguishment of debt at date of modification (note 7)	177,234	--
Modification of the 10% promissory note	--	100,000
Gain on extinguishment of debt at date of modification	--	(38,097)
Balance end of period	2,384,045	706,803
Current portion of 10% senior convertible notes	1,176,728	--
	\$ \$	706,803
	1,207,317	

During the nine months ended September 30, 2007, the Company issued an aggregate of \$1,435,000 of its 10% senior convertible notes. \$625,000 of the notes were issued for cash; \$810,000 of the notes were issued as consideration for the cancellation of \$636,407 in principal of and \$173,593 in accrued interest on its promissory notes (note 3). Under the terms of the notes, the holders are permitted, at any time, to convert all or a portion of the outstanding principal plus accrued interest into common stock of the company. The rate of conversion for \$400,000 of the notes is one common share for each \$0.03 of debt converted; the rate of conversion for \$1,035,000 of the notes is one common share for each \$0.06 of debt converted. Holders of \$835,000 of the notes were not able to exercise their conversion feature until such time as the authorized capital of the Company was increased to at least 120,000,000 common shares. On October 4, 2007, at the Company's Annual General Meeting, an increase in the Company's authorized capital from 100,000,000 to 300,000,000 common shares, was approved; as such, the contingent conversion feature of the notes was resolved, and accounted for, as of that date.

The Company has the option of pre-paying all or any portion of the balance outstanding on the notes at any time, without penalty or bonus, with the permission of the holders. Interest is payable quarterly, in arrears, at such time as the holder requests payment, and may, at the Company's option, be paid either in cash or in common shares of the Company. If interest is paid in common shares, the number of shares required for settlement will be calculated using a 10% discount to the average closing price of the common stock, as listed on the exchange where the Company's common stock is traded, for

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

4. 10% Senior convertible notes (continued)

the ten days prior to the date the interest is due to the holder. \$350,000 of the notes issued during this period are secured by a first position lien on all of the assets of the Company; the remaining \$1,085,000 of the notes are unsecured.

Holders of the \$625,000 notes issued for cash were granted 1,675,000 common shares of the Company upon issuance of the notes. In accordance with APB 14, Accounting for Convertible Debt and Debt issued with Stock Purchase Warrants, \$107,666, representing the relative fair value of the common shares at the issuance date, was allocated to the common shares par value and additional paid in capital.

Holders of the \$810,000 notes issued in consideration for the cancellation of promissory notes were granted 810,000 common shares of the Company, such grant to take effect only if and when the authorized capital of the Company was increased to at least 120,000,000 common shares. On October 4, 2007, at the Company's Annual General Meeting, an increase in the Company's authorized capital from 100,000,000 to 300,000,000 common shares, was approved. Accordingly, the \$52,902 relative fair value of the contingent share grant relating to these notes was not recorded at the date of issuance, but was recorded as a reclassification from notes payable to share capital and additional paid-in capital on October 4, 2007, being the date on which the contingency was resolved.

Holders of the \$810,000 notes issued in consideration for the cancellation of promissory notes were also granted 1,620,000 Series K warrants, which entitle the holders to purchase 1,620,000 common shares of the Company at an exercise price of \$0.03 per share, and expire on June 21, 2011. In accordance with APB 14, Accounting for Convertible Debt and Debt issued with Stock Purchase Warrants, \$102,515, representing the relative fair value of the warrants at the issuance date, was allocated to additional paid in capital.

At the date of issuance of \$600,000 of the notes issued for cash, the conversion feature of the notes was in-the-money. The intrinsic value of this beneficial conversion feature was \$87,846. In accordance with EITF 98-05, Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios and EITF 00-27, Application of Issue No. 98-5 to Certain Convertible Instruments, this amount was recorded as additional

paid-in capital.

\$25,000 of the notes issued for cash, as well as the \$810,000 face value of notes issued as consideration for the cancellation of principal and accrued interest on its 12% promissory notes were not convertible until such time as the authorized capital of the Company was increased to at least 120,000,000 common shares. On October 4, 2007, at the Company's Annual General Meeting, an increase in the Company's authorized capital from 100,000,000 to 300,000,000 common shares, was approved. Accordingly, the \$427,708 intrinsic value of the contingent conversion feature of these notes was not recorded at the date of issuance, but was recorded as a reclassification from notes payable to additional paid-in capital on October 4, 2007, being the date on which the contingency was resolved.

On March 9, 2007, in conjunction with the issuance of \$200,000 10% senior convertible notes, \$900,000 of 10% senior convertible notes issued during 2006 were amended as follows: the ratio at which the outstanding principal plus accrued interest thereon could be converted into common stock of the Company was changed from \$0.10 to \$0.06; interest on the notes shall be accrued until such time as the holder requests payment. These amendments resulted in the terms of the amended notes being substantially different from the terms of the original notes, as that term is defined in EITF 96-19: Debtor's Accounting for a Modification or Exchange of Debt Instruments. Accordingly the Company accounted for the modification as an extinguishment of the original debt, which resulted in a loss on the extinguishment of debt of \$177,234.

On July 9, 2007, a holder of the Company's 10% senior convertible notes exercised the conversion option and converted \$50,000 in principal and \$3,027 in accrued interest in exchange for 572,194 shares of common stock.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

4. 10% Senior convertible notes (continued)

The following table summarizes information regarding the 10% senior convertible notes outstanding at September 30, 2007:

	Face Value	Unamortized Discount	Carrying Value	Conversion Rate	Maturity Date
Maturing within one year	\$ 150,000	\$ 15,095	\$ 134,905	\$0.03	July 2008
	1,125,000	271,018	853,982	0.06	Oct 2007 July 08
	200,000	12,159	187,841	0.10	July 2008
	1,475,000	298,272	1,176,728		
Long term	250,000	81,394	168,606	0.03	May 2009
	810,000	89,096	720,904	0.06	June 2009
	500,000	182,193	317,807	0.10	Oct 2008
	1,560,000	352,683	1,207,317		
Total	\$ 3,035,000	\$ 650,955	\$2,384,045		

At September 30, 2007, \$1,250,000 face value of the 10% senior convertible notes was secured by a first position lien on all of the assets of the Company. The remaining \$1,785,000 was unsecured.

5. Stockholders Equity

(a) Common stock transactions

During the nine months ended September 30, 2007, the Company issued an aggregate of 659,001 shares of its common stock, valued at \$39,887, to the holders of the 10% senior convertible notes, in satisfaction of \$31,604 of accrued interest on the notes. A loss on settlement of accrued interest payable in the amount of \$8,283 (note 7) was recognized in connection with this transaction.

During the nine months ended September 30, 2007, the Company issued an aggregate of 3,025,000 shares of its common stock, valued at \$139,150, for services rendered. \$139,150, representing the value of services rendered under these contracts has been included in selling, general and administrative expenses for the period ended September 30, 2007.

During the nine months ended September 30, 2007, the Company issued 1,000,000 shares of its common stock, valued at \$37,000, in consideration for consulting services rendered during the period from October 1, 2006 to January 16, 2007. \$31,519, representing the value of services rendered prior to December 31, 2006, was included in accrued liabilities at December 31, 2006 and in selling, general and administrative expenses for the year then ended. \$5,481, representing the value of services rendered during the nine months ended September 30, 2007, has been included in selling, general and administrative expense for the period then ended.

During the nine months ended September 30, 2007, the Company issued an aggregate of 1,275,000 shares of its common stock, valued at \$47,175, in settlement of accrued liabilities totaling \$127,499. A gain on settlement of debt in the amount of \$80,324 was recognized in connection with this transaction.

In connection with the issuance of the Company's 10% senior convertible notes during the nine months ended September 30, 2007 (note 4), the Company issued a total of 1,675,000 of its common shares, valued at \$107,666, to the holders of the notes.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

5. Stockholders Equity (continued)

(a) Common stock transactions (continued)

In connection with the issuance of the Company's 10% senior convertible notes during the nine months ended September 30, 2007 (note 4), the Company also granted holders of the notes an additional 810,000 common shares of the Company, which shares were not issued during the period, in accordance with the terms of the notes, which precluded issuing the shares until such time as the authorized capital of the Company was increased to at least 120,000,000 common shares. On October 4, 2007, at the Company's Annual General Meeting, an increase in the Company's authorized capital from 100,000,000 to 300,000,000 common shares was approved; the related shares were issued subsequently.

On July 9, 2007, a holder of the Company's 10% senior convertible notes (note 4) exercised the conversion option and converted \$50,000 in principal and \$3,027 in accrued interest in exchange for 572,194 shares of common stock.

During the nine months ended September 30, 2007, the Company issued 149,333 shares of its common stock, valued at \$6,659, in consideration for finance fees relating to the issuance of the Company's 10% senior secured convertible notes (note 4). 100,000 of the shares were prepaid, which resulted in a gain on the transaction of \$2,300.

(b) Transactions involving stock purchase warrants

During the nine months ended September 30, 2007, the Company issued an aggregate of 3,120,000 series K warrants. The Series K warrants entitle the holders to purchase a total of 3,120,000 common shares of the Company at an exercise price of \$0.03 per share, are exercisable at any time, and expire on June 21, 2011. The \$211,190 fair value of the warrants at date of issuance was calculated using the Black Scholes option pricing model with the following

assumptions: expected dividend yield 0%; risk-free interest rate of 5%; expected volatility of 134%; and an expected life of 4 years.

1,620,000 of the Series K warrants were granted in connection with the issuance of the Company's 10% senior convertible notes on June 21, 2007 (note 4). \$102,515, representing the relative fair value of the warrants at the issuance date, was allocated to additional paid in capital.

1,500,000 of the Series K warrants were issued as partial consideration for consulting services which were to have been rendered over a two-year period commencing May 15, 2007. On July 25, 2007 the contract was terminated; consequently, \$108,675, representing the value of the Series K warrants issued in connection with this contract, has been included in selling, general and administrative expenses for the nine months ended September 30, 2007.

Effective May 15, 2007, the exercise price of the Company's Series I warrants was adjusted from \$0.10 to \$0.03, in accordance with the terms of the warrant agreements, which provide for the conversion rate to be adjusted at such time as the Company issues debt or equity instruments having a conversion rate lower than the rate then in effect for the Series I warrants. On May 15, 2007, the Company issued 10% senior convertible notes (note 4) having a conversion rate of \$0.03.

On May 31, 2007, the 3,146,000 Series F warrants expired.

On July 9, 2007, the 1,635,000 Series E warrants were repurchased and cancelled for cash consideration of \$1,000. At the date of repurchase, the fair value of the Series E warrants was nil, as calculated using the Black Scholes option pricing model with the following assumptions: expected dividend yield 0%; risk-free interest rate of 4.85%; expected volatility of 188%; and an expected life of .48 years. The \$1,000 cost of repurchasing the Series E warrants has been included in general and administrative expenses.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

5. Stockholders Equity (continued)

(b) Transactions involving stock purchase warrants (continued)

Following is a summary of stock purchase warrants outstanding at September 30, 2007 and December 31, 2006:

	Exercise		Outstanding	Outstanding
			September	December
	Price	Expiry	30,	31,
			2007	2006
Series E	\$0.33	December, 2007	--	1,635,000
Series F	0.50	May, 2007	--	3,146,000
Series I	0.03	March, 2009	3,513,333	3,513,333
Series J	0.15	June, 2008	650,000	650,000
Series K	0.03	June, 2011	3,120,000	--
			7,283,333	8,944,833

(c)

Transactions involving stock options

The Company has two incentive equity plans, under which a maximum of 7,000,000 options to purchase 7,000,000 common shares may be granted to officers, employees and consultants of the Company. The granting of options, and the terms associated with them, occurs at the discretion of the board of directors, who administers the plan. As of September 30, 2007, there were a total of 6,305,000 options granted under these plans, with exercise prices ranging from \$0.04 to \$0.33, and expiry dates ranging from May 7, 2008 to June 19, 2012. All of these options are fully vested. 695,000 options remained available for grant under these plans as of September 30, 2007.

On June 11, 2007, the Company effected a cancellation of 2,667,302 options previously issued to employees and consultants, through a repurchase of the options from the holders for aggregate consideration of \$2,661 to be settled in cash, and 5,100,000 newly issued options. The newly issued options vested immediately; have an exercise price of \$0.04; and an expiry date of June 10, 2012, with provision for early forfeiture in the event the holder ceases to be engaged by the Company prior to the stated expiry date. The incremental fair value of these options at the date of grant was \$106,933, determined using the following weighted average assumptions: expected dividend yield 9%; risk-free interest rate of 5.06%; expected volatility of 168%; and an expected life of 5 years.

Also on June 11, 2007, the Company granted 900,000 options as partial consideration for consulting services which were to have been rendered over a two-year period commencing May 15, 2007. On July 25, 2007 the contract was terminated; consequently, \$20,970, representing the value of the options issued in connection with this contract, has been included in selling, general and administrative expenses for the nine months ended September 30, 2007. The fair value of these options was determined using the following weighted average assumptions: expected dividend yield 9%; risk-free interest rate of 5.06%; expected volatility of 168%; and an expected life of 5 years.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

5. Stockholders Equity (continued)

(c)

Transactions involving stock options (continued)

Following is a summary of stock options outstanding at September 30, 2007 and December 31, 2006:

	Nine months ended September 30,		Year ended December 31,	
	2007		2006	
	# of Options	Weighted Average Exercise Price	# of Options	Weighted Average Exercise Price
Options outstanding, beginning of period	3,447,302	\$ 0.50	5,252,302	\$ 0.50
Granted	6,000,000	0.04	100,000	0.67
Cancelled	(2,667,302)	0.50	--	--
Expired	(408,000)	0.60	(1,655,000)	0.51
Forfeited	(67,000)	0.67	(250,000)	0.57
Options outstanding, end of period	6,305,000	\$ 0.05	3,447,302	\$ 0.50
Options exercisable, end of period	6,305,000	\$ 0.05	3,297,302	\$ 0.49

The following table summarizes information regarding stock options outstanding at September 30, 2007:

Exercise price	Options Outstanding			Options Exercisable		
	Number outstanding At 09/30/07	Weighted average remaining contractual life	Weighted average exercise price	Number outstanding At 09/30/07	Weighted average exercise price	
\$ 0.33	305,000	0.6 years	\$ 0.33	305,000	\$ 0.33	
0.04	6,000,000	4.7 years	0.04	6,000,000	0.04	
	6,305,000		\$ 0.05	6,305,000	\$ 0.05	

(d)

Stock-based compensation

The following table presents the total of stock-based compensation included in the expenses of the Company for the three and nine months ended September 30, 2007 and 2006:

	Three Months Ended		Nine Months Ended	
	September 30, 2007	September 30, 2006	September 30, 2007	September 30, 2006
Selling, general and administrative	129,721	44,877	436,324	200,427
Research and development	--	3,313	24,372	9,939
Total stock-based compensation included in expenses	\$ 129,721	\$ 48,190	\$ 460,696	\$ 210,366

6. Interest and Financing Costs

Interest and financing costs include accrued interest, accretion and amortization of deferred financing costs relating to the 10% senior convertible notes; accrued interest on the promissory notes; and the interest portion of capital lease payments.

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

7. Gain (loss) on extinguishment of debt and accrued liabilities

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2007	2006	2007	2006
Loss on settlement of \$31,603 of accrued interest on 10% senior secured convertible notes (note 5(a))	\$ --	\$ --	\$ (8,283)	\$ --
Gain on issuance of 1,275,000 common shares, valued at \$47,175, in settlement of accrued liabilities totaling \$127,499 (note 5(a))	--	--	80,324	--
Gain on issuance of 100,000 common shares, valued at \$3,700, as partial consideration for finance fees payable in connection with \$200,000 in principal amount of the 10% senior convertible notes	--	--	2,300	--
Loss recognized on the modification of the 10% senior convertible notes (note 4)	--	--	(177,234)	--
Gain on extinguishment of 10% senior convertible promissory notes	--	38,097	--	38,097
Loss on issuance of 250,000 common shares, valued at \$28,750, in satisfaction of accounts payable totaling \$25,000	--	(3,750)	--	(3,750)
	\$ --	\$ 34,347	\$ \$(102,893)	\$ 34,347

8. Loss Per Share

For the purposes of the loss per share computation, the weighted average number of common shares outstanding has been used. Had the treasury stock method been applied to the unexercised stock options and warrants, the effect on the loss per share would be anti-dilutive.

The following securities could potentially dilute basic earnings per share in the future but have not been included in diluted earnings per share because their effect was anti-dilutive:

	September 30, 2007	September 30, 2006
Stock options	6,305,000	4,902,302
Series E stock purchase warrants	--	2,155,000
Series F stock purchase warrants	--	3,146,000
Series G stock purchase warrants	--	400,000
Series H stock purchase warrants	--	2,652,500
Series I stock purchase warrants	3,513,333	3,513,333
Series J stock purchase warrants	650,000	--
Series K stock purchase warrants	3,120,000	--
	13,588,333	16,769,135

9. Related Party Transactions

Included in promissory notes payable is \$8,499 payable to a company controlled by a director of the Company, and \$19,830 payable to a director. \$2,841 in accrued interest charges relating to these notes is included in accrued liabilities at September 30, 2007 (December 31, 2006: \$221); \$2,620 is included in interest and finance charges for the period then ended (September 30, 2006: \$nil).

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

10. Commitments

In April 2007, the lease period of the agreement for office space was extended for a period of three years. Minimum annual rent payable under this contract, including operating costs, is approximately as follows:

2007	\$	19,882
2008		79,527
2009		79,527
2010		26,509
Total	\$	205,445

Rental expense for the period, which is included in selling, general and administrative expenses, has been reduced by sublease income of \$18,610 (2006 - \$23,823). The sublease arrangement was discontinued effective August 31, 2007.

Rent expense incurred under the operating lease for the nine months ended September 30, 2007, net of sublease income was \$70,867 (2006 - \$88,152).

11. Supplementary Cash Flow Information

The Company paid no income taxes during the nine months ended September 30, 2007, nor during the nine months ended September 30, 2006. Interest paid in cash during the nine months ended September 30, 2007 and September 30, 2006 was \$942 and \$2,130, respectively.

Non-cash financing activities are excluded from the consolidated condensed statement of cash flows. The following is a summary of such activities for the nine months ended September 30, 2007 and September 30, 2006:

	2007	2006
Debt issuance costs	\$ 23,960	\$ 99,050
Issuance of 250,000 shares of the Company's common stock, valued at		
\$28,750, in settlement of accounts payable in the amount of \$25,000	--	28,750
Issuance of 659,001 shares of the Company's common stock, valued at		
\$39,887, in settlement of interest payable in the amount of \$31,603	39,887	--
Issuance of 1,275,000 shares of the Company's common stock, valued		
at \$47,175, in settlement of accrued liabilities totaling \$127,499	47,175	--
Issuance of 1,025,000 shares of the Company's common stock, valued at		
\$38,150, in satisfaction of consulting fees payable, \$31,519 of which was		
included in accrued liabilities at December 31, 2006	38,150	--
Issuance of 3,000,000 shares of the Company's common stock, valued at		
\$138,000, in respect of consulting services rendered	138,000	--
Payable to employees and consultants with respect to the repurchase		
of options issued in prior periods	2,661	--
	\$	\$
	289,833	127,800

VALIDIAN CORPORATION AND SUBSIDIARIES

A DEVELOPMENT STAGE ENTERPRISE

Notes to Consolidated Condensed Financial Statements

September 30, 2007

(Unaudited)

12. Subsequent events

At the Company's Annual General Meeting (AGM) on October 4, 2007, the Company's Restated Articles of Incorporation were amended to increase the number of shares of the Company's common stock authorized for issuance from 100,000,000 to 300,000,000, and the number of the Company's preferred stock authorized for issuance was increased from 7,000,000 to 50,000,000; the Company's 2004 Amended Incentive Equity Plan, which amends and restates the Company's 2004 Incentive Equity Plan to, among other things, increase the maximum number of stock options that may be granted from 3,087,698 to 6,087,698 and to increase the maximum number of stock options which may be granted to any one participant from 2,000,000 to 3,000,000, was approved.

On October 4, 2007, the Company issued 810,000 shares of its common stock to holders of its 10% senior convertible notes, pursuant to the terms of the notes which were issued on June 21, 2007, and which granted the shares subject to the Company's authorized capital being increased to at least 120,000,000 common shares, which increase took effect at the Annual General Meeting.

Also on October 4, 2007, the contingency relating to the conversion feature of \$835,000 of the Company's 10% senior convertible notes was resolved. The notes were issued on June 21, 2007, and were convertible subject to the authorized capital of the Company being increased to at least 120,000,000 common shares, which increase took effect at the Annual General Meeting.

During the period from October 1, 2007 to November 9, 2007, the Company issued an aggregate of \$44,856 of its promissory notes, of which \$24,856 were issued to companies controlled by the directors of the Company.

Item 2. Management's Discussion and Analysis or Plan of Operations

FORWARD-LOOKING INFORMATION

We caution readers that certain important factors may affect our actual results and could cause such results to differ materially from any forward-looking statements that we make in this report. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. This report contains statements that constitute forward-looking statements. These forward-looking statements can be identified by the use of predictive, future-tense or forward-looking terminology, such as believes, anticipates, expects, estimates, plans, or similar terms. These statements appear in a number of places in this report and include statements regarding our intent, belief or current expectations with respect to many things, some of which are:

- trends affecting our financial condition or results of operations for our limited history;
- our business and growth strategies;
- our technology;
- the Internet; and
- our financing plans.

We caution readers that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties. In fact, actual results most likely will differ materially from those projected in the forward-looking statements as a result of various factors. Some factors that could adversely affect actual results and performance include:

- our limited operating history;

- our lack of sales to date;
- our requirements for additional capital and operational funding;
- the failure of our technology and products to perform as specified;
- the discontinuance of growth in the use of the Internet;
- the enactment of new adverse government regulations; and
- the development of better technology and products by others.

You should carefully consider and evaluate all of these factors. In addition, we do not undertake to update forward-looking statements after we file this report with the SEC, even if new information, future events or other circumstances have made them incorrect or misleading.

CRITICAL ACCOUNTING POLICIES

We prepare our financial statements in accordance with generally accepted accounting principles in the United States of America. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant accounting policies and methods used in preparation of the financial statements are described in note 2 to our 2006 Consolidated Financial Statements included in our Annual Report on Form 10-KSB for the year ended December 31, 2006. We evaluate our estimates and assumptions on a regular basis, based on historical experience and other relevant factors. Actual results could differ materially from these estimates and assumptions. The following critical accounting policies are impacted by judgments, assumptions and estimates used in preparation of our September 30, 2007 Interim Consolidated Condensed Financial Statements.

Revenue recognition:

For sales of product licenses, we recognize revenue in accordance with Statement of Position 97-2, Software Revenue Recognition (SOP 97-2), as amended by Statement of Position 98-9, Software Revenue Recognition with Respect to Certain Transactions , issued by the American Institute of Certified Public Accountants. Revenue from sale of product licenses is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable and collectibility is probable.

Revenue from product support contracts is recognized ratably over the life of the contract. Revenue from services is recognized at the time such services are rendered.

For contracts with multiple elements such as product licenses, product support and services, we follow the residual method. Under this method, the total fair value of the undelivered elements of the contract, as indicated by vendor specific objective evidence, is deferred and subsequently recognized in accordance with the provisions of SOP 97-2. The difference between the total contract fee and the amount deferred for the undelivered elements is recognized as revenue related to the delivered elements. Vendor specific objective evidence for support and consulting services is obtained from contracts where these elements have been sold separately. Where we cannot determine the fair value of all of the undelivered elements, revenue is deferred until such time as it can be determined or until all of the elements are delivered.

Long-lived assets:

We perform impairment tests on our long-lived assets if events or changes in circumstances indicate that an impairment loss may have occurred. We estimate the useful lives of capital assets and deferred charges based on the nature of the asset, historical experience and the terms of any supplier contracts. The valuation of long-lived assets is based on the amount of future net cash flows these assets are estimated to generate. Revenue and expense projections are based on management's estimates, including estimates of current and future industry conditions. A significant change to these assumptions could impact the estimated useful lives or valuation of long-lived assets resulting in a change to depreciation or amortization expense and impairment charges.

Research and development expenses:

We expense all of our research and development expenses in the period in which they are incurred. At such time as our product is determined to be commercially available, we will capitalize those development expenditures that are related to the maintenance of the commercial products, and amortize these capitalized expenditures over the estimated life of the commercial product. The estimated life of the commercial product will be based on management's estimates, including estimates of current and future industry conditions. A significant change to these assumptions could impact the estimated useful life of our commercial product resulting in a change to amortization expense and impairment charges.

Stock based compensation:

Effective January 1, 2006, the Company adopted the provisions of Financial Accounting Standards Board Statement No. 123R Share-Based Payment a revision of FAS 123 (SFAS 123R) to account for its stock-based payments. SFAS 123R requires all share-based payments, including stock options granted by the Company to its employees, to be recognized as expenses, based on the fair value of the share-based payments at the date of grant. For purposes of estimating the grant date fair value of stock-based compensation, the Company uses the Black Scholes option-pricing model, and has elected to treat awards with graded vesting as a single award. The fair value of awards granted is recognized as compensation expense on a straight-line basis over the requisite service period, which in the Company's circumstances is the stated vesting period of the award.

In adopting SFAS 123R, the Company has applied the modified-prospective transition method. Under this method, the Company will recognize compensation costs for all share-based payments granted, modified, or settled after January 1, 2006, as well as for any awards that were granted prior to January 1, 2006 for which the requisite service had not been provided as of that date (unvested awards). Under the modified prospective method, prior periods are not adjusted.

RESULTS OF OPERATIONS

The Three Months Ended September 30, 2007 Compared to the Three Months Ended September 30, 2006

Revenue: We had no revenue during the three months ended September 30, 2007, nor during the three months ended September 30, 2006. Since August 1999 we have directed all of our attention towards the completion, and sales and marketing of, our software applications. We believe that if we are successful in our development and sales and marketing efforts, we will generate a source of revenue in the future from sales and/or licensing of our software applications.

Selling, general and administrative expenses: Selling, general and administrative expenses consist primarily of personnel costs, professional fees, insurance, communication expenses, occupancy costs and other miscellaneous costs associated with supporting our research and development, sales and marketing and investor relations activities.

During the three months ended September 30, 2007, we incurred a total of \$418,121, including \$288,400 in cash-based expenses and \$129,721 in stock-based expenses, as compared to \$481,349, of which \$436,472 was cash-based and \$44,877 was stock-based expense, during the three months ended September 30, 2006. There was an overall decrease in selling, general and administrative expenses of \$63,228 (13%), comprised of a \$148,072 (34%) decrease in the cash-based component of this expense, which was partially offset by a \$84,844 (189%) increase in the stock-based component.

We have made efforts to reduce these costs, through measures such as reducing the number of personnel, including not replacing an officer and director on his retirement in December of 2006; reducing cash-based fees to investor relations consultants; decreasing the size of our leased premises; reducing the number of trade shows in which we participate; and delaying production of new promotional material. These reductions were partially offset by an increase of 6% in the average exchange rate for the Canadian dollar in relation to the United States dollar for the three months ended September 30, 2007 as compared to the three months ended September 30, 2006. Many of our selling, general and administrative expenses are incurred in Canadian dollars and reported in United States dollars; consequently this fluctuation has resulted in an overall increase in reported expenses. We will continue to carefully monitor the costs of these departments as we work within current budgetary limits leading up to the full commercial release of our products.

The stock-based component of selling, general and administrative expense for the three months ended September 30, 2007 consisted of the amortization of prepaid consulting fees recorded during first quarter of 2007 on the issuance of common stock in consideration for services rendered; and the amortization of the remaining balance of prepaid consulting fees recorded during the second quarter of 2007 on the issuance of options and warrants in consideration for consulting services which were to have been rendered over the two-year contract period. The remaining prepaid balance was expensed in full when the contract was terminated in August 2007. The stock-based component of this expense for the three-month period ended September 30, 2006 consisted of the amortization of prepaid consulting fees recognized on the issuance of warrants during 2003; and the fair value of employee stock options earned during the period, for which there was no comparable expense during the three months ended September 30, 2007.

Research and development expenses: Research and development expenses consist primarily of personnel costs and consulting expenses directly associated with the development of our software applications. During the three months ended September 30, 2007, we incurred \$35,276, which was comprised of cash-based expenses only, developing our software applications, compared to \$192,496, of which \$189,183 was cash-based and \$3,313 was stock-based expense, during the three months ended September 30, 2006. Total research and development expenses decreased by \$157,220 (82%), comprised of a \$153,907 (81%) decrease in the cash-based component, and a \$3,313 (100%) decrease in the stock-based component of this expense. The decrease in the cash-based component is due primarily to the temporary suspension, effective July 1, 2007, of the work which had been conducted by the Europe-based contract development group on our development activities, in order to allow time to plan the direction and focus of future development activities within a more limited budget. This group resumed work on our development activities during the third quarter of 2007. Additionally, the development management position was contracted on a part-time basis during the three months ended September 30, 2007, whereas this was a full-time position during the three months ended September 30, 2006.

Stock-based research and development expenses for the three months ended September 30, 2006 consisted of the fair value of employee stock options earned during the period, for which there was no comparable transaction during the three months ended September 30, 2007.

Interest and financing costs: Interest and financing costs during the three months ended September 30, 2007 and 2006 consisted of costs associated with our 10% senior convertible notes, our promissory notes payable and interest

on the capital lease. During the three months ended September 30, 2007, we incurred \$295,068 in interest and financing costs, an increase of \$167,307 (131%) over the \$127,761 in interest and financing costs incurred during the three months ended September 30, 2006.

The \$295,068 in interest and financing costs we incurred during the three months ended September 30, 2007 is comprised of \$78,718 of interest payable to the holders of our debt; \$179,465 of accretion of the equity components of our 10% senior convertible notes; \$36,627 of amortization of deferred financing costs; and \$258 in interest on the capital lease. The \$127,761 in interest and financing costs we incurred during the three months ended September 30, 2006 is comprised of \$64,008 of interest payable to the holders of our debt; \$54,325 of accretion of the equity components of our 10% senior convertible notes; \$8,896 of amortization of deferred financing costs; and \$532 in interest on the capital lease.

The increase in interest and financing costs is a result of an increase of \$2,535,000 in the principal balance of our 10% senior convertible notes during the period from September 2006 to September 2007, which was partially offset by a net decrease of \$275,951 in the principal outstanding on our promissory notes during the same period. This net increase in principal outstanding on our debt instruments resulted in a higher balance on which coupon based interest was charged; there was also an increase in value of the equity based components of our 10% senior convertible notes, relating to new notes issued, which resulted in higher accretion charges; and additional financing costs relating to these new notes resulted in an increase in amortization of deferred finance charges.

Net loss: We incurred a loss of \$791,141 (\$0.02 per share) for the three months ended September 30, 2007, compared to a loss of \$785,966 (\$0.02 per share) for the three months ended September 30, 2006. Our revenues and future profitability are substantially dependent on our ability to:

- raise additional capital to fund operations;
- license the software applications to a sufficient number of clients;
- be cash-flow positive on an ongoing basis;
- modify the successful software applications, over time, to provide enhanced benefits to then-existing users; and
- successfully develop related software applications.

The Nine Months Ended September 30, 2007 Compared to the Nine Months Ended September 30, 2006

Revenue: We had no revenue during the nine months ended September 30, 2007, nor during the nine months ended September 30, 2006. Since August 1999 we have directed all of our attention towards the completion, and sales and marketing of, our software applications. We believe that if we are successful in our development and sales and marketing efforts, we will generate a source of revenues in the future from sales and/or licensing of our software applications.

Selling, general and administrative expenses: Selling, general and administrative expenses consist primarily of personnel costs, professional fees, insurance, communication expenses, occupancy costs and other miscellaneous costs associated with supporting our research and development, sales and marketing and investor relations activities. During the nine months ended September 30, 2007, we incurred a total of \$1,348,354, including \$912,030 in cash-based expenses and \$436,324 in stock-based expenses, as compared to \$1,476,149, of which \$1,275,722 was cash-based and \$200,427 was stock-based expense, during the nine months ended September 30, 2006. There was an overall decrease in selling, general and administrative expenses of \$127,795 (9%), comprised of a \$363,692 (29%) decrease in the cash-based component, which was partially offset by a \$235,897 (118%) increase in the stock-based component of this expense.

We have made efforts to reduce these costs, through measures such as reducing the number of personnel, including not replacing an officer and director on his retirement in December of 2006; reducing cash-based fees to investor relations consultants; decreasing the size of our leased premises; reducing the number of trade shows in which we participate; and delaying production of new promotional material. These reductions were partially offset by an increase of 2% in the average exchange rate for the Canadian dollar in relation to the United States dollar for the nine months ended September 30, 2007 as compared to the nine months ended September 30, 2006. Many of our selling, general and administrative expenses are incurred in Canadian dollars and reported in United States dollars; consequently, this fluctuation has resulted in an overall increase in reported expenses. We will continue to carefully monitor the costs of these departments as we work within current budgetary limits leading up to the full commercial release of our products.

The stock-based component of selling, general and administrative expense for the nine month period ended September 30, 2007 consisted of the amortization of prepaid consulting fees recognized on the issuance of warrants during 2003; amortization of prepaid consulting fees recorded during first quarter of 2007 on the issuance of common stock in consideration for services rendered and to be rendered; the incremental value of stock options issued in June 2007 in exchange for the repurchase and cancellation of options issued in prior years; the fair value of common stock issued as compensation for services rendered during the period; the fair value of employee stock options earned during the period; and the amortization of the remaining balance of prepaid consulting fees recorded during the second quarter of 2007 on the issuance of options and warrants in consideration for consulting services which were to have been rendered over the two-year contract period. The remaining prepaid balance was expensed in full when the contract was terminated in August 2007. The stock-based component of this expense for the nine-month period ended September 30, 2006 consisted of the amortization of prepaid consulting fees recognized on the issuance of warrants during 2003; the fair value of common stock issued as compensation for services rendered during the period; and the fair value of employee stock options earned during the period.

Research and development expenses: Research and development expenses consist primarily of personnel costs and consulting expenses directly associated with the development of our software applications. During the nine months ended September 30, 2007, we incurred \$626,262, including \$601,890 in cash-based expenses and \$24,372 in stock-based expenses, developing our software applications, compared to \$792,487, of which \$782,548 was cash-based and \$9,939 was stock-based expense, during the nine months ended September 30, 2006. Total research and development expenses decreased by \$166,225 (21%), comprised of a \$180,658 (23%) decrease in the cash-based component, which was partially offset by a \$14,433 (145%) increase in the stock-based component of this expense. The decrease in the cash-based component is due primarily to the temporary suspension, effective July 1, 2007, of the work which had been conducted by the Europe-based contract development group on our development activities, in order to allow time to plan the direction and focus of future development activities within a more limited budget. This group resumed work on our development

activities during the third quarter of 2007. Additionally, the development management position was contracted on a part-time basis during the nine months ended September 30, 2007, whereas this was a full-time position during the nine months ended September 30, 2006. These decreases were partially offset by a significant increase in costs incurred during the period for the development of a software component by another software development contractor, designed to assist a customer in implementing our software, as compared with similar costs incurred during the nine months ended September 30, 2006. We also incurred costs to develop software which would allow one of our products to work in conjunction with another company's software during the nine months ended September 30, 2007, for which there was no comparable expense during the nine months ended September 30, 2006.

Stock-based research and development expenses for the nine months ended September 30, 2007 consisted of the incremental value of options issued to personnel in exchange for the repurchase and cancellation of options previously issued, for which there was no comparable transaction during the nine months ended September 30, 2006. Stock-based expenses for the nine months ended September 30, 2006 consisted of the fair value of employee stock options earned during the period, for which there was no comparable transaction during the nine months ended September 30, 2007.

Interest and financing costs: Interest and financing costs during the nine months ended September 30, 2007 and 2006 consisted of costs associated with our 10% senior convertible notes, our promissory notes payable and interest on the capital lease. During the nine months ended September 30, 2007, we incurred \$721,645 in interest and financing costs, an increase of \$530,041 (277%) over the \$191,604 in interest and financing costs incurred during the nine months ended September 30, 2006.

The \$721,645 in interest and financing costs we incurred during the nine months ended September 30, 2007 is comprised of \$211,038 of interest payable to the holders of our debt; \$413,035 of accretion of the equity components of our 10% senior convertible notes; \$96,630 of amortization of deferred financing costs; and \$942 in interest on the capital lease. The \$191,604 in interest and financing costs we incurred during the nine months ended September 30, 2006 is comprised of \$94,752 of interest payable to the holders of our debt; \$81,943 of accretion of the equity components of our 10% senior convertible notes; \$13,168 of amortization of deferred financing costs; and \$1,741 in interest on the capital lease.

The increase in interest and financing costs is a result of an increase of \$2,535,000 in the principal balance of our 10% senior convertible notes during the period from September 2006 to September 2007, which was partially offset by a net decrease of \$275,951 in the principal outstanding on our promissory notes during the same period. This net increase in principal outstanding on our debt instruments resulted in a higher balance on which coupon based interest was charged; there was also an increase in value of the equity based components of our 10% senior convertible notes, relating to new notes issued, which resulted in higher accretion charges; and additional financing costs relating to these new notes resulted in an increase in amortization of deferred finance charges.

Loss on extinguishment of debt and accrued liabilities: During the nine months ended September 30, 2007, we recorded a net loss on extinguishment of debt in the amount of \$102,893. This total is comprised of a number of transactions involving the restructuring of our debt securities, and the issuance of our common stock in settlement of

accounts payable and accrued liabilities. During the nine months ended September 30, 2006, we had a net gain of \$34,347 on the extinguishment of debt, which was comprised of a gain of \$38,097 on the modification of the terms of our 10% senior convertible notes; and a loss of \$3,750 on the issuance of our common stock in satisfaction of accounts payable.

Net loss: We incurred a loss of \$2,909,706 (\$0.06 per share) for the nine months ended September 30, 2007, compared to a loss of \$2,477,628 (\$0.07 per share) for the nine months ended September 30, 2006. Our revenues and future profitability are substantially dependent on our ability to:

- raise additional capital to fund operations;
- license the software applications to a sufficient number of clients;
- be cash-flow positive on an ongoing basis;
- modify the successful software applications, over time, to provide enhanced benefits to then-existing users; and
- successfully develop related software applications.

LIQUIDITY AND CAPITAL RESOURCES

General: Since inception, we have funded our operations from private placements of debt and equity securities. In addition, until September 1999 we derived revenues from consulting contracts with affiliated parties, the proceeds of which were used to fund operations. Until such time as we are able to generate adequate revenues from the licensing of our software applications, we cannot assure that we will be successful in raising additional capital, or that cash from the

issuance of debt securities, the exercise of existing warrants and options, and the placements of additional equity securities, if any, will be sufficient to fund our long-term research and development and selling, general and administrative expenses.

Our cash and cash equivalents decreased by \$6,236 during the nine months ended September 30, 2007, from a balance of \$7,780 at December 31, 2006, to \$1,544 at September 30, 2007. Our net loss of \$2,909,706 during the period, and resulting cash used in operations of \$853,851, were partially offset by an increase in cash resulting from the issuance of \$625,000 of 10% senior convertible notes, and \$232,312 from the issuance of promissory notes. Our cash and cash equivalents decreased by \$69,276 during the nine months ended September 30, 2006 primarily as a result of our net loss of \$2,477,628, and resulting cash used in operations of \$1,186,767, which were partially offset by an increase in cash resulting from the issuance of \$600,000 10% senior convertible notes, and \$551,177 in promissory notes.

Our independent registered public accountants included an explanatory paragraph to their audit opinion issued in connection with our consolidated financial statements for the year ended December 31, 2006. It states that our economic viability is dependent on our ability to finalize the development of our principal products, generate sales and finance operational expenses, and that these factors, together with our lack of revenues to date; our negative working capital; our loss for the year, as well as negative cash flow from operating activities in the same period; and our accumulated deficit, raise substantial doubt regarding our ability to continue as a going concern. At September 30, 2007, we had negative working capital of \$3,259,576 and an accumulated deficit during the development stage of \$27,552,888; for the nine months then ended we had a net loss of \$2,909,706, and negative cash flow from operations of \$853,851; and note 1 to our unaudited interim condensed financial statements for the period ended September 30, 2007 also discusses the continuing substantial doubt regarding our ability to continue as a going concern.

We achieved our first commercial sale during the third quarter of 2005, however we were unable to recognize revenue in connection with this sale, as all of the criteria required for us to do so as set out in our accounting policies were not met. During April 2006 we determined that collection of the amount invoiced in connection with this sale was unlikely, and have recorded an allowance against the entire amount, as an offset against deferred revenue. On January 1, 2006 we entered into an agreement with a Value Added Reseller (VAR), pursuant to which we granted the VAR a license to sell our software to the VAR s customers for a period of three years. Our fee for this license, excluding applicable sales taxes, was \$155,000, of which \$151,650 has been collected. We will recognize revenue in connection with this sale once all of the criteria required for us to do so as set out in our accounting policies, have been met.

We anticipate additional commercial sales during the fourth quarter of 2007, however we cannot be assured that this will be the case. During the nine months ended September 30, 2007 one of our full-time employees left the Company; another of our full-time employees left the Company in October 2007. We have no plans to hire additional personnel during the next 6 months. We have not made, nor do we expect to make, any material commitments for capital equipment expenditures during the next 12 months.

We have an immediate requirement for additional working capital in order to proceed with our business plan. We review our cash needs and sources on a month-to-month basis and we are currently pursuing appropriate opportunities to raise additional capital to fund operations. Additional sources of capital could involve issuing equity or debt. Since

February 2006, we have engaged financial advisers to provide advice to us with respect to the raising of capital. However, additional funding may not be available to us on reasonable terms, if at all. The perceived risk associated with the possible sale of a large number of shares could cause some of our stockholders to sell their stock, thus causing the price of our stock to decline. In addition, actual or anticipated downward pressure on our stock price due to actual or anticipated issuance of stock could cause some institutions or individuals to engage in short sales of our common stock, which may itself cause the price of our stock to decline. We may be unable to raise additional capital if our stock price is too low. A sustained inability to raise capital could force us to limit or curtail our operations.

We expect the level of our future operating expenses to be driven by the needs of our research and development and marketing programs offset by the availability of funds. In addition, we have since inception made an effort to keep our expenses relatively low and conserve available cash until we begin generating sufficient operating cash flow.

Sources of Capital: Our principal sources of capital for funding our business activities have been the private placements of debt and equity securities. During the nine months ended September 30, 2007, we issued \$232,312 of promissory notes and \$625,000 of 10% senior convertible notes, which generated cash for funding operations. During this period we issued a further \$810,000 in 10% senior convertible notes in consideration for the cancellation of \$810,000 of principal and accrued interest on our promissory notes, which will reduce the overall cash-based interest charges on our debt. We also issued 572,194 common shares on the redemption of \$53,027 in principal and accrued interest on our 10% senior convertible notes, which will further reduce future cash-based interest charges, and will also reduce the amount of cash which would have become payable on maturity of the notes. In addition, we issued 4,025,000 common shares in consideration for consulting services rendered and to be rendered, 149,333 common shares in consideration for finance fees, 1,275,000

common shares in settlement of accrued liabilities, 900,000 options and 1,500,000 Series K warrants in consideration of consulting services rendered; and 659,001 common shares issued in settlement of accrued interest on our 10% senior convertible notes, all of which reduced our requirement for cash. We also issued 5,100,000 new options as partial consideration for the cancellation of 2,667,302 options previously issued, as an incentive to current personnel, which also reduced our requirement for cash.

During the period from October 1, 2007 to November 9, 2007, we issued an aggregate of \$44,856 of promissory notes, the proceeds of which were used to fund operations.

The Company has not entered into any off-balance sheet arrangements which would have provided the Company with a source of capital.

Uses of Capital: Over the past several years, we have scaled our development activities to the level of available cash resources. Cash-based research and development expenses for the nine months ended September 30, 2007 decreased by approximately 23% as compared to the nine months ended September 30, 2006, as a result of cash conservation efforts. Cash-based selling, general and administrative expenses for the nine months ended September 30, 2007 decreased by approximately 29% as compared to the nine months ended September 30, 2006, due to several factors, including a reduction in selling and marketing initiatives, and as explained more fully under Results of Operations.

Our plans with respect to future staffing will be dependant upon our ability to raise additional capital. We have not entered into any off-balance sheet arrangements which would have resulted in our use of capital.

The cost to implement appropriate controls and procedures to ensure compliance with Section 404 of the Act is included in our budget for 2007.

ITEM 3. CONTROLS AND PROCEDURES

The term disclosure controls and procedures is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, or the Exchange Act. This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission.

In connection with the audit of our consolidated financial statements for the years ended December 31, 2006 and 2005, our independent registered public accounting firm advised the Board of Directors and management of certain

significant internal control deficiencies that they considered to be, in the aggregate, a material weakness. In particular, our independent registered public accounting firm identified the following weaknesses in our internal control system: (1) a lack of segregation of duties; and (2) the lack of timely preparation of certain back up schedules. The independent registered public accounting firm indicated that they considered these deficiencies to be reportable conditions as that term is defined under standards established by the American Institute of Certified Public Accountants. A material weakness is a significant deficiency in one or more of the internal control components that alone or in the aggregate precludes our internal controls from reducing to an appropriately low level of risk that material misstatements in our financial statements will not be prevented or detected on a timely basis. We considered these matters in connection with the period-end closing of accounts and preparation of the related consolidated financial statements and determined that no prior period financial statements were materially affected by such matters. Notwithstanding the material weakness identified by our independent registered public accountants, we believe that the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operation and cash flows of the Company as of, and for, the periods represented in this report.

Our size has prevented us from being able to employ sufficient resources at this time to enable us to have an adequate level of supervision and segregation of duties within our internal control system. We will continue to monitor and assess the costs and benefits of additional staffing within the Company.

We were unable to eliminate the identified weaknesses with respect to the period covered by this report. However, we began to implement some of the steps identified below to remediate the material weakness to the extent that our size and resources allowed us, commencing during the second quarter of 2004. Set forth below is a discussion of the significant internal control deficiencies which have not been remediated.

Lack of segregation of duties. Since commencing the development phase of our operations in August 1999, our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our internal control system. Until the beginning of the fourth quarter of 2005, we had only three people involved with the processing of accounting entries: the Office Administrator, the Controller and the Chief

Financial Officer. It was therefore difficult to effectively segregate accounting duties. During the fourth quarter of 2005, we retained the services of a part-time independent consultant to assist in performing routine, month end accounting procedures. This consultant left the Company effective May 2006, however, and has not been replaced.

While we strive to segregate duties as much as practicable, there is insufficient volume of transactions to justify additional full time staff. As a result, this significant internal control deficiency had not been remediated as of the end of the period covered by this report, nor do we know if we will be able to remediate this weakness in the foreseeable future. However, we will continue to monitor and assess the costs and benefits of additional staffing.

Lack of timely preparation of back up schedules. Throughout 2005 and until the third quarter of 2006, we were able to complete most of our back up schedules prior to the arrival of our independent registered public accountants audit staff. However, we did not file our quarterly report on Form 10-QSB for the quarter ended September 30, 2006 until November 24, 2006, nor did we file our annual report on form 10-KSB for the year ended December 31, 2006 until May 18, 2007, which late filings were partially the result of our lack of timely preparedness. Most of our back up schedules relating to the first and second quarters of 2007 were completed prior to the arrival of our independent registered public accountants audit staff, and our quarterly reports on Form 10-QSB for these periods were timely filed. However, we believe that this material weakness had not been remediated as of the end of the period covered by this report. One of our objectives in hiring the part-time consultant during the fourth quarter of 2005 to perform routine, month end accounting procedures, was to improve the timeliness of preparation of back up schedules and thus permit us to complete our financial reporting on a more timely basis. This individual provided some assistance in these areas, however the arrangement did not work out as anticipated, and the consultant was no longer engaged by us as of May 2006. Effective during the latter part of the quarter ended March 31, 2007, we commenced the process of reviewing and expanding our formal month-end procedures, with the objective of improving the timeliness of the preparation of future quarterly reports and related back up schedules.

If we are unable to remediate the identified material weakness, there is a more than remote likelihood that a material misstatement to our SEC reports will not be prevented or detected, in which case investors could lose confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on our ability to raise additional capital and could also have an adverse effect on our stock price.

As required by the SEC rules, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Report. This evaluation was performed under the supervision and with the participation of our management, including the President and Chief Executive Officer and Chief Financial Officer and Treasurer. Based upon that evaluation, our President and Chief Executive Officer and Chief Financial Officer and Treasurer have concluded that our controls and procedures were not effective as of the end of the period covered by this Report due to the existence of the significant internal control deficiencies described above.

No change in our internal control over financial reporting occurred during the quarter ended September 30, 2007 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On October 4, 2007, the Company issued 810,000 shares of its common stock to an accredited investor pursuant to the terms of the 10% senior convertible notes which were issued to the investor on June 21, 2007.

The foregoing securities were issued in reliance upon the exemption provided by Section 4(2) of the Securities Act of 1933, as amended, and the rules promulgated thereunder.

Item 6. Exhibits

(a) Exhibits.

- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the small business issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VALIDIAN CORPORATION

By: /s/ Bruce Benn

Bruce Benn

President and Chief Executive Officer

(principal executive officer)

Dated: November 18, 2007

By: /s/ Ronald Benn

Ronald Benn

Chief Financial Officer and Treasurer

(principal financial and accounting officer)

Dated: November 18, 2007

